GRAIL, Inc.

GRAIL, Inc. is an American biotechnology company headquartered in Menlo Park, California, dedicated to the early detection of cancer. Its mission is to alleviate the global burden of cancer by identifying the disease in its earliest, potentially more treatable and curable stages. The company leverages next-generation sequencing, population-scale clinical studies, and advanced machine learning to achieve this goal.

The company's primary product is the Galleri test, a multi-cancer early detection (MCED) blood test. This innovative test is designed to screen for over 50 types of cancer before symptoms manifest, including many for which no recommended screening tests currently exist. GRAIL operates within the biotechnology and oncology market segments, focusing on transforming cancer screening.

GRAIL, Inc. became an independent publicly traded company on Nasdaq under the ticker "GRAL" in June 2024, following its spin-off from Illumina due to regulatory mandates. In January 2026, the company completed the submission of its Premarket Approval (PMA) application for the Galleri test to the U.S. Food and Drug Administration. Josh Ofman, MD, MSHS, was appointed as the new CEO in March 2026. The company aims to establish a new standard of care in cancer screening, having reported over 180,000 commercial Galleri tests sold as of March 2024.

Latest updates

GRAIL Management to Present at BofA Healthcare Conference

Event summary

  • GRAIL management will present at the BofA Securities 2026 Health Care Conference on May 12, 2026, at 8:40 a.m. PT.
  • The presentation will be webcast live and archived on GRAIL's investor relations website.
  • GRAIL focuses on early cancer detection using next-generation sequencing and machine learning.
  • The company's platform supports screening, precision oncology, and recurrence monitoring.

The big picture

GRAIL's participation in the BofA Securities conference underscores the ongoing investor interest in the multi-cancer early detection market, which holds significant potential but faces challenges related to clinical validation, reimbursement, and patient adoption. The presentation provides a platform for GRAIL to articulate its strategy and address investor concerns regarding the commercial viability of its technology. The company's valuation will be heavily influenced by its ability to demonstrate real-world impact and generate sustainable revenue.

What we're watching

Investor Sentiment
The conference presentation offers a key opportunity to gauge investor sentiment regarding GRAIL's progress in commercialization and clinical validation of its multi-cancer early detection tests.
Regulatory Landscape
The presentation may shed light on how GRAIL is navigating evolving regulatory pathways for early cancer detection tests, particularly concerning reimbursement and clinical utility.
Competitive Dynamics
The content of the presentation will likely reveal how GRAIL is positioning itself against competitors in the increasingly crowded multi-cancer early detection market.
CID: 791